Abingworth LLP

13F Filings History

Latest 13F report
Q3 2024 - Nov 8, 2024
Signature - Title
John Heard - General Counsel
Location
London, United Kingdom
Summary
This page shows a list of all the recent 13F filings made by Abingworth LLP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Abingworth LLP didn't report any stock holdings as of Q3 2024. Carlyle Group Inc. is reporting for Abingworth LLP.
Holdings Value

Carlyle Group Inc. is reporting for Abingworth LLP:

Name Holdings Value Location File Number
Carlyle Group Inc. $954M Washington, DC 028-15025
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q3 2024 13F-NT 11/8/2024, 05:00 PM
Q2 2024 13F-NT 8/9/2024, 04:47 PM
Q1 2024 13F-NT 5/3/2024, 04:39 PM
Q4 2023 0 13F-NT 2/2/2024, 04:47 PM
Q3 2023 0 13F-NT 11/3/2023, 04:44 PM
Q2 2023 0 13F-NT 8/4/2023, 04:41 PM
Q1 2023 0 13F-NT 5/5/2023, 05:01 PM
Q4 2022 19 $304M $0 -$103M -$103M PCVX, VRNA, VERA, HLVX, ACET 13F-HR 2/10/2023, 04:28 PM
Q3 2022 19 $292M +$4.92M -$79.2M -$74.2M PCVX, VERA, HLVX, ACET, VRNA 13F-HR 11/10/2022, 04:48 PM
Q2 2022 21 $312M +$19.9M -$14.7M +$5.25M PCVX, SRRA, VERA, ACET, HLVX 13F-HR 8/15/2022, 06:30 AM
Q1 2022 20 $352M +$18.9M $0 +$18.9M PCVX, VERA, ACET, SRRA, JSPR 13F-HR 5/16/2022, 07:00 AM
Q4 2021 20 $413M +$8.72M $0 +$8.72M PCVX, VERA, JSPR, EFTR, ACET 13F-HR 2/16/2022, 11:26 AM
Q3 2021 20 $441M +$126M -$1.73M +$124M PCVX, EFTR, JSPR, VERA, PHAT 13F-HR 11/15/2021, 06:05 AM
Q2 2021 19 $324M +$56.7M $0 +$56.7M PCVX, PHAT, VERA, SIEN, RPHM 13F-HR 8/16/2021, 06:30 AM
Q1 2021 17 $290M +$22.9M $0 +$22.9M PCVX, PHAT, ACET, VRNA, SIEN 13F-HR 5/17/2021, 06:11 AM
Q4 2020 15 $292M +$43.1M -$119M -$75.7M PCVX, PHAT, SLNO, VRNA, NCNA 13F-HR 3/1/2021, 11:18 AM
Q3 2020 17 $468M +$27.3M -$43.1M -$15.8M PCVX, PSNL, PHAT, SLNO, CRSP 13F-HR 11/16/2020, 06:15 AM
Q2 2020 16 $355M +$139M -$3.97M +$135M PCVX, PSNL, PHAT, CRSP, SLNO 13F-HR 8/14/2020, 03:27 PM
Q1 2020 16 $151M +$9.09M -$879K +$8.21M PSNL, PHAT, CRSP, SLNO, XCUR 13F-HR 5/14/2020, 06:05 AM
Q4 2019 16 $207M +$48.9M -$6.65M +$42.3M PSNL, PHAT, CRSP, SIEN, SLNO 13F-HR 2/14/2020, 06:05 AM
Q3 2019 14 $158M +$15.8M -$38M -$22.3M PSNL, CRSP, XCUR, SIEN, SLNO 13F-HR 11/14/2019, 06:06 AM
Q2 2019 14 $261M +$148M -$13.8M +$134M PSNL, CRSP, SIEN, AVDR, SLNO 13F-HR 8/14/2019, 06:09 AM
Q1 2019 14 $112M +$13.4M -$12.5M +$856K CRSP, SIEN, CHMA, SLNO, AVDR 13F-HR 5/15/2019, 06:15 AM
Q4 2018 16 $110M +$7.98M -$4.32M +$3.67M CRSP, SIEN, VRNA, SLNO, CHMA 13F-HR 2/14/2019, 06:16 AM
Q3 2018 16 $168M +$11.3M -$11.9M -$644K CRSP, SIEN, VRNA, PRTK, OBSVF 13F-HR 11/14/2018, 06:15 AM
Q2 2018 16 $175M +$7.22M -$38.8M -$31.5M CRSP, SIEN, PRTK, OBSVF, GTXI 13F-HR 8/14/2018, 07:00 AM
Q1 2018 16 $161M +$2.98M -$18.1M -$15.1M CRSP, SIEN, PRTK, GTXI, OBSVF 13F-HR 5/15/2018, 06:08 AM
Q4 2017 17 $138M $0 -$4.44M -$4.44M CRSP, SIEN, PRTK, CBAY, OBSVF 13F-HR 2/14/2018, 06:10 AM
Q3 2017 18 $144M +$8.61M -$16.8M -$8.22M CRSP, SIEN, PRTK, CBAY, CHMA 13F-HR 11/14/2017, 06:13 AM
Q2 2017 16 $126M $0 -$3.45M -$3.45M CRSP, PRTK, SIEN, CBAY, CASC 13F-HR 8/14/2017, 06:02 AM
Q1 2017 17 $134M +$6.72M -$2.18M +$4.54M CRSP, PRTK, SIEN, CBAY, CASC 13F-HR 5/15/2017, 07:36 AM
Q4 2016 18 $119M +$53.2M -$13.7M +$39.4M CRSP, PRTK, SIEN, NOVN, CHMA 13F-HR 2/14/2017, 06:04 AM
Q3 2016 20 $104M +$4.8M -$7.61M -$2.82M SIEN, PRTO, PRTK, CEMP, CHMA 13F-HR 11/14/2016, 07:20 AM
Q2 2016 20 $95.5M +$4.78M -$533K +$4.25M PRTK, PRTO, SIEN, TBRA, CEMP 13F-HR 8/12/2016, 06:03 AM
Q1 2016 19 $108M +$256K $0 +$256K PRTK, CHMA, PRTO, SIEN, CEMP 13F-HR 5/13/2016, 06:16 AM
Q4 2015 18 $166M +$6.11M -$369K +$5.74M CHMA, PRTO, PRTK, SIEN, CEMP 13F-HR 2/16/2016, 07:22 AM
Q3 2015 17 $171M +$46.1M -$21.1M +$25M CHMA, PRTO, PRTK, SIEN, EVAR 13F-HR 11/13/2015, 06:49 AM
Q2 2015 16 $216M +$19M -$47.5M -$28.6M SIEN, PRTO, PRTK, AMRN, EVAR 13F-HR 8/14/2015, 06:47 AM
Q1 2015 17 $235M +$1.02M -$157M -$156M SIEN, PRTK, SUPN, DRNA, PRTO 13F-HR 5/14/2015, 06:03 AM
Q4 2014 16 $352M +$108M -$56K +$108M RNA, PRTK, SIEN, PTLA, SUPN 13F-HR 2/13/2015, 06:12 AM
Q3 2014 13 $167M +$25.7M -$14.2M +$11.5M RNA, EVAR, SUPN, PTLA, DRNA Restatement 11/25/2014, 03:07 PM
Q2 2014 12 $215M +$1.58M -$7.63M -$6.05M RNA, SUPN, PTLA, DRNA, AMRN 13F-HR 8/14/2014, 06:53 AM
Q1 2014 13 $181M +$36.3M $0 +$36.3M RNA, DRNA, SUPN, PTLA, AMRN 13F-HR 5/20/2014, 06:33 PM
Q4 2013 11 $133M $0 $0 PTLA, RNA, SUPN, AMRN, CEMP 13F-HR 2/14/2014, 08:47 AM